Abstract
The prophylactic efficacy of poly(ICLC) (stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid) against Rift Valley fever virus infection in Swiss-Webster mice was dependent on the treatment schedule. The treatment schedule was optimized by ranking the results of various treatments by the Cox proportional-hazard model based on the incremental relative risk of death. With this ranking procedure, the schedule of choice was three doses of 20 micrograms each given 5 days apart. This regimen yielded a 90% survival rate. Additional parameters were determined, including the timing of the first and second drug dose, the temporal relationship of these treatments to the day of challenge, and the minimal effective dose (1 microgram per mouse).
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baer G. M., Shaddock J. H., Moore S. A., Yager P. A., Baron S. S., Levy H. B. Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis. 1977 Aug;136(2):286–291. doi: 10.1093/infdis/136.2.286. [DOI] [PubMed] [Google Scholar]
- Chirigos M. A., Welker R., Schlick E., Saito T., Ruffmann R. Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC. Prog Clin Biol Res. 1984;161:467–479. [PubMed] [Google Scholar]
- Harrington D. G., Hilmas D. E., Elwell M. R., Whitmire R. E., Stephen E. L. Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly (I).poly (C). Am J Trop Med Hyg. 1977 Nov;26(6 Pt 1):1191–1198. doi: 10.4269/ajtmh.1977.26.1191. [DOI] [PubMed] [Google Scholar]
- Lampkin B. C., Levine A. S., Levy H., Krivit W., Hammond D. Phase II trial of poly(I,C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. J Biol Response Mod. 1985 Oct;4(5):531–537. [PubMed] [Google Scholar]
- Levy H. B., Baer G., Baron S., Buckler C. E., Gibbs C. J., Iadarola M. J., London W. T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975 Oct;132(4):434–439. doi: 10.1093/infdis/132.4.434. [DOI] [PubMed] [Google Scholar]
- McFarlin D. E., Bever C. T., Salazar A. M., Levy H. B. A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod. 1985 Oct;4(5):544–548. [PubMed] [Google Scholar]
- Stephen E. L., Hilmas D. E., Levy H. B., Spertzel R. O. Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis. 1979 Mar;139(3):267–272. doi: 10.1093/infdis/139.3.267. [DOI] [PubMed] [Google Scholar]
- Stephen E. L., Sammons M. L., Pannier W. L., Baron S., Spertzel R. O., Levy H. B. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis. 1977 Jul;136(1):122–126. doi: 10.1093/infdis/136.1.122. [DOI] [PubMed] [Google Scholar]
- Talmadge J. E., Adams J., Phillips H., Collins M., Lenz B., Schneider M., Schlick E., Ruffmann R., Wiltrout R. H., Chirigos M. A. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 1985 Mar;45(3):1058–1065. [PubMed] [Google Scholar]
- Wiltrout R. H., Salup R. R., Twilley T. A., Talmadge J. E. Immunomodulation of natural killer activity by polyribonucleotides. J Biol Response Mod. 1985 Oct;4(5):512–517. [PubMed] [Google Scholar]